RxDoctor Payments Data

David Campbell, MD

Hematology & Oncology · Grass Valley, CANPI 1750373239

Payments from drug & device makers

$348in general payments, 2019–2025

Across 14 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$139
  • Johnson & Johnson$120
  • Acrotech Biopharma Inc.$38
  • Eisai Inc.$22
  • E.r. Squibb & Sons, L.L.C.$19
  • Amgen$11

What the payments were for

  • Food & beverage$11132%
  • Education$23768%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$139
Johnson & Johnson(2 entities)3$120
Acrotech Biopharma Inc.3$38
Eisai Inc.1$22
E.r. Squibb & Sons, L.L.C.1$19
Amgen1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348 in reported general payments places this provider in the 15th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$574,519
Medicare patients
757
Services billed
7,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide52$1,084,127
BrukinsaZanubrutinib60$815,197
Lenalidomide59$784,689
XtandiEnzalutamide34$489,765
CalquenceAcalabrutinib Maleate33$415,405
SprycelDasatinib31$359,885
IbrancePalbociclib25$357,567
MekinistTrametinib Dimethyl Sulfoxide22$318,252
TafinlarDabrafenib Mesylate22$310,425
LorbrenaLorlatinib12$251,440
ZejulaNiraparib Tosylate12$215,522
VerzenioAbemaciclib13$194,677
XembifyImmune Globulin,gamma(Igg)klhw39$124,980
InqoviDecitabine/Cedazuridine14$116,653
VenclextaVenetoclax24$113,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Lorbrena, Eliquis$139$637,14171 claims
E.r. Squibb & Sons, L.L.C.Sprycel$19$359,88531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Grass Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →